$103.960
-1.029 (-0.99%)At close
HAE News
HAE Events
Haemonetics Stock Rises 16.2%
Haemonetics is up 16.2%,…
Haemonetics Stock Rises 15.2%
Haemonetics is up 15.2%,…
Haemonetics Up 9% to $98.50 on CSL Plasma Supply Agreement
Haemonetics up 9% at $98.50 in pre-market on CSL Plasma supply agreement
Raises FY27 Revenue Outlook to Increase 5%-8%
Raises FY27 revenue view to up 5%-8% from up 4%-7%.
Haemonetics Q1 Revenue $339.38M, Exceeds Expectations
Reports Q1 revenue $339.38M, consensus $327.89M. Chris Simon, Haemonetics' CEO, stated: "We had a strong start to fiscal 2027, gaining Plasma share, sustaining Blood Management Technologies momentum, and returning Interventional Technologies to growth. With our evolved portfolio, transformed operating model and disciplined execution, we are strengthening our competitive position and demonstrating the durable growth of our diversified businesses. We raised full-year guidance, and Haemonetics is well-positioned to deliver sustainable long term growth and shareholder value."
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.